Frontline Treatment Scheme VTD (Bortezomib/Thalidomide/Dexamethasone) in Patients With Multiple Myeloma Transplant Candidates at Our Center

Autor:	M. Garcia-Fortes, R. Garcia-Sanchez, M. Rivas-Luque, M.P. Queipo de Llano-Temboury, A. Campos-Garrigues, I. Caparros-Miranda, J.J. Ruiz-Arredondo, A. Gonzalez-Fernandez, A. Rosell-Más, A. Fernandez-Fernandez, F. Cabrera Ruiz
Rok vydání:	2015
Předmět:	Oncology Bortezomib/thalidomide Cancer Research medicine.medical_specialty business.industry Hematology medicine.disease Internal medicine medicine In patient business Dexamethasone Multiple myeloma medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 15:e168-e169
ISSN:	2152-2650
DOI:	10.1016/j.clml.2015.07.388
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::41d98bef524a899cca6e67a21c2ba955 https://doi.org/10.1016/j.clml.2015.07.388 Zobrazit plný text záznamu Full Text from ScienceDirect